What it sells
AI drug safety.
Business model breakdown
Buyer: who owns the budget?
UnverifiedHead of discovery or safety/toxicology at pharma and biotech R&D.
Trigger: what makes them buy now?
UnverifiedLate-stage failures from missed target safety liabilities; need early, standardised target de-risking.
Workflow: what inputs become what output?
Replaces manual literature scavenging and static slide-deck target profiles with harmonised data from 35+ sources, auto-generated referenced safety reports, collaborative auditable editing and alerts on new literature/filings.
Economics: what it saves and how it charges
UnverifiedEnterprise software licences to pharma; no prices shown.
Distribution: how it reaches customers
Demo-led: 'Book a demo' is the primary call to action.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-02-11 | — | €3.15M | — | news.google.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.